Milan Laboratories (india) Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Milan Laboratories (india) Private Limited Pharmaceutical Export Portfolio Dataset — 5 Products, $4.6M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Milan Laboratories (india) Private Limited — Pharmaceutical Exporter Profile (2026) | 5 Products, $4.6M Trade | TransData Nexus

Milan Laboratories (india) Private Limited

Indian Pharmaceutical Exporter · Advanced Antibiotics Specialist · $4.6M Total Trade · DGFT Verified

Milan Laboratories (india) Private Limited is an Indian pharmaceutical exporter with a total trade value of $4.6M across 5 products in 5 therapeutic categories. Based on 166 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Flucloxacillin ($1.8M), Clotrimazole ($1.6M), Rivaroxaban ($853.4K).

Milan Laboratories (india) Private Limited — Export Portfolio & Destination Treemap

Milan Laboratories (india) Private Limited pharmaceutical export portfolio — 5 products across 5 therapeutic categories. Source: Indian Customs (DGFT).

Who is Milan Laboratories (india) Private Limited? — Company Overview & Market Position

Milan Laboratories (India) Private Limited, established on March 26, 2003, is a private pharmaceutical company headquartered in Thane, Maharashtra, India. The company is registered under the Corporate Identification Number (CIN) U24230MH2003PTC139736. It operates as a non-government company limited by shares, with an authorized capital of ₹2.00 crore and a paid-up capital of ₹1.98 crore.

The company specializes in the manufacturing and export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Over the years, Milan Laboratories has expanded its reach to over 43 countries, holding more than 300 marketing authorizations worldwide.

What Does Milan Laboratories (india) Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Flucloxacillin$1.8M 2Clotrimazole$1.6M

Product Portfolio — Top 5 by Export Value

Milan Laboratories (india) Private Limited exports 5 pharmaceutical products across 5 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Flucloxacillin	Advanced Antibiotics	$1.8M	36	3.7%	4
2	Clotrimazole	Antifungals	$1.6M	82	1.7%	11
3	Rivaroxaban	Cardiovascular	$853.4K	31	1.6%	14
4	Clonazepam	CNS & Psychiatric	$264.8K	14	0.2%	7
5	Quinine	Antimalarial & Antiparasitic	$150.0K	3	0.8%	10

Milan Laboratories (india) Private Limited exports 5 pharmaceutical products across 5 therapeutic categories with a total export value of $4.6M. The top category is Advanced Antibiotics (38.9% of portfolio), followed by Antifungals (33.7%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Milan Laboratories (india) Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Milan Laboratories operates WHO-cGMP compliant manufacturing facilities, ensuring adherence to international quality standards. The company's manufacturing plant is located at 303/304, 3rd Floor, Odyssey IT Park, Wagle Estate, MIDC, Thane (W), Maharashtra, India. Specific details regarding the plant's capacities and specializations are not publicly disclosed.

3Key Leadership

The leadership team of Milan Laboratories comprises:

Upendra Madan Despande – Director
Rohini Rajeev Dongre – Director
Sharwari Upendra Deshpande – Director (appointed on March 13, 2025)
Rahul Rajeev Dongre – Director (appointed on May 23, 2025)

These directors collectively oversee the strategic direction and operations of the company.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Milan Laboratories (india) Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Milan Laboratories has established a presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has achieved over 300 marketing authorizations worldwide, indicating a significant footprint in these regions. While specific regulatory filings and approvals are not publicly detailed, the company's adherence to WHO-cGMP standards suggests compliance with international regulatory requirements.

2Emerging Markets

Milan Laboratories has expanded its reach to over 43 countries, including regions in Africa, Latin America, and Southeast Asia. The company's adherence to WHO-cGMP standards facilitates access to these emerging markets, as WHO prequalification is often a prerequisite for entry.

3Geographic Strategy

Milan Laboratories demonstrates a diversified geographic strategy by exporting to over 43 countries across various continents. This broad market presence mitigates concentration risk and positions the company to leverage growth opportunities in both developed and emerging markets. The strategic direction appears focused on expanding global reach while maintaining compliance with international quality standards.

Milan Laboratories (india) Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding Milan Laboratories' FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. However, the company's adherence to WHO-cGMP standards suggests a commitment to meeting international regulatory requirements, which is often a prerequisite for FDA approvals.

2WHO & EU GMP

Milan Laboratories operates WHO-cGMP compliant manufacturing facilities, indicating adherence to international quality standards. While specific certifications such as WHO prequalification or EU GMP certificates are not publicly disclosed, the company's compliance with WHO-cGMP standards suggests a commitment to meeting international regulatory requirements.

3CDSCO & Indian Regulatory

Milan Laboratories holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), the national regulatory authority in India. Specific details regarding state drug controller approvals and export No Objection Certificates (NOCs) are not publicly available. However, the company's adherence to WHO-cGMP standards and its active status with the Ministry of Corporate Affairs indicate compliance with Indian regulatory requirements.

Milan Laboratories (india) Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Milan Laboratories operates in a competitive pharmaceutical industry, exporting to over 43 countries and holding more than 300 marketing authorizations worldwide. While specific competitors are not identified, the company's adherence to WHO-cGMP standards and its diversified product portfolio position it favorably in the global market.

2Key Differentiators

Milan Laboratories' key differentiators include its adherence to WHO-cGMP standards, a diversified product portfolio encompassing five products across five therapeutic categories, and a significant export value of $4.6 million USD over 166 shipments. These factors contribute to the company's competitive advantage in the pharmaceutical export market.

3Strategic Position

Milan Laboratories' strategic direction appears focused on expanding its global footprint by exporting to over 43 countries and holding more than 300 marketing authorizations worldwide. The company's adherence to WHO-cGMP standards and its diversified product portfolio suggest a commitment to quality and regulatory compliance. Future outlook may involve further expansion into emerging markets and continuous enhancement of product offerings.

Buyer Due Diligence Brief — Evaluating Milan Laboratories (india) Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Milan Laboratories has demonstrated a consistent track record in pharmaceutical exports, with a total export value of $4.6 million USD over 166 shipments. The company's adherence to WHO-cGMP standards and its diversified product portfolio indicate reliability and a commitment to quality. However, specific indicators of reliability, such as customer feedback or third-party audits, are not publicly available.

2Certifications to Verify

Importers should verify the following certifications when considering Milan Laboratories as a supplier:

WHO-GMP Certification: To confirm adherence to international manufacturing standards.
EU GMP Certification: To ensure compliance with European Union manufacturing standards.
ISO Certification: To verify quality management systems.

These certifications can typically be verified through the company's official website or by contacting the relevant regulatory bodies.

Frequently Asked Questions — Milan Laboratories (india) Private Limited

How many pharmaceutical products does Milan Laboratories (india) Private Limited export from India?

Milan Laboratories (india) Private Limited exports 5 pharmaceutical products across 5 therapeutic categories. The top exports are Flucloxacillin ($1.8M), Clotrimazole ($1.6M), Rivaroxaban ($853.4K), Clonazepam ($264.8K), Quinine ($150.0K). Total export value is $4.6M.

What is Milan Laboratories (india) Private Limited's total pharmaceutical export value?

Milan Laboratories (india) Private Limited's total pharmaceutical export value is $4.6M, based on 166 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Milan Laboratories (india) Private Limited cover?

Milan Laboratories (india) Private Limited exports across 5 therapeutic categories. The largest are Advanced Antibiotics (38.9%, 1 products), Antifungals (33.7%, 1 products), Cardiovascular (18.4%, 1 products).

Get Full Milan Laboratories (india) Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.